Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) is a micro-cap Healthcare company valued at ₹1,444 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Jagsonpal Pharmaceuticals Limited last traded at ₹218.1, modestly down 0.46% on the day.

Recent developments

On 2026-06-29, Jagsonpal Pharmaceuticals Limited announced an acquisition, including an agreement to acquire, which may expand its operations and product portfolio.

Financial performance

The company's annual revenue rose 6.8% to ₹287 crore, while annual net profit fell 21.7% to ₹43 crore. In the latest quarter, revenue grew 8.2% to ₹82 crore and net profit increased 19.9% to ₹13 crore, showing improvement in profitability compared to the same quarter a year earlier. The net profit margin narrowed to 15.0% from 20.4% in the prior year.

Valuation multiples

The stock trades at 34.1 times earnings, broadly in line with the Healthcare median of 32.0, 5.56 times book value. It yields 1.7%.

Things to watch

The company's net profit margin has declined by 5.4 percentage points, indicating pressure on profitability. The stock is 12.4% below its 52-week high, suggesting a pullback from recent peak levels. Promoter holdings increased slightly, but foreign institutional holdings decreased in the quarter.

Where it stands

Jagsonpal Pharmaceuticals reported improved quarterly results with revenue and net profit both rising year-over-year, but annual net profit fell despite revenue growth. The company's net profit margin has declined, and the stock is trading below its 52-week high. The acquisition announcement may provide growth opportunities, but the narrowing margin remains a key challenge.

Summarised by DocStoX's model on 2026-10-04 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.